Nektar Therapeutics: Pay

Nektar Therapeutics paid its 4 named executives $24.8M in total in FY2022 (Dec). CEO Howard W. Robin was paid $11.3M of that.

Pay$100 in the stock at the end of FY20 → $13
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Howard W. RobinPresident and Chief Executive Officer
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
2 years
Mark A. WilsonFormer Chief Legal Officer
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
2 years
Jonathan Zalevsky, Ph.D.Chief Research and Development Officer
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 12 peers with pay on file was $6.2M. The CEO of Nektar Therapeutics was paid $6.3M, 1% above the median.

  1. 1Arcus Biosciences
  2. 2IDEAYA Biosciences
  3. 3Praxis Precision Medicines
  4. 4Vir Biotechnology
  5. 5Corvus Pharmaceuticals
  6. 6Vera Therapeutics
  7. 7Nektar Therapeutics
  8. 8Celldex Therapeutics
  9. 9Compass Therapeutics
  10. 10Intellia Therapeutics
  11. 11Relay Therapeutics
  12. 12Olema Pharmaceuticals
  13. 13Gossamer Bio
  14. 14Amylyx PharmaceuticalsNot disclosed
  15. 15Astria TherapeuticsNot disclosed
  16. 16Dianthus TherapeuticsNot disclosed
  17. 17Immunome BothellNot disclosed
  18. 18Kodiak SciencesNot disclosed
  19. 19RezoluteNot disclosed
  20. 20Viridian TherapeuticsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.